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Background: Krabbe disease is an autosomal recessive lysosomal storage disorder caused by mutations in the
GALC gene. The most common mutation in the Caucasian population is a 30-kb deletion of exons 11 through 17.
There are few other reports of intragenic GALC deletions or duplications, due in part to difficulties detecting them.
Methods and results: We used gene-targeted array comparative genomic hybridization (CGH) to analyze the GALC
gene in individuals with Krabbe disease in whom sequence analysis with 30-kb deletion analysis identified only one
mutation. In our sample of 33 cases, traditional approaches failed to identify two pathogenic mutations in five
(15.2%) individuals with confirmed Krabbe disease. The addition of array CGH deletion/duplication analysis to the
genetic testing strategy led to the identification of a second pathogenic mutation in three (9.1%) of these five
individuals. In all three cases, the deletion or duplication identified through array CGH was a novel GALC mutation,
including the only reported duplication in the GALC gene, which would have been missed by traditional testing
methodologies. We report these three cases in detail. The second mutation remains unknown in the remaining two
individuals (6.1%), despite our full battery of testing.
Conclusions: Analysis of the GALC gene using array CGH deletion/duplication testing increased the two-mutation
detection rate from 84.8% to 93.9% in affected individuals. Better mutation detection rates are important for
improving molecular diagnosis of Krabbe disease, as well as for providing prenatal and carrier testing in family
members.
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Krabbe disease, also called globoid cell leukodystrophy,
is an autosomal recessive lysosomal storage disorder in-
volving progressive damage to the white matter of the
central and peripheral nervous systems (reviewed in [1]).
The disease is caused by deficiency of the enzyme galac-
tocerebrosidase (GALC), which leads to an inability to
degrade galactolipids found mainly in the myelin sheath
[2]. Symptoms include spasticity, irritability, and devel-
opmental delay and regression, which progress to a
severe decerebrate condition with no voluntary move-
ments [3]. While the age of onset and progression of the
disease is variable, 85-90% of affected individuals de-
velop symptoms in the first six months of life, with a
median survival of 17 months [1,4]. Death is often due* Correspondence: mhegde@emory.edu
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reproduction in any medium, provided the orto respiratory infections or cerebral hyperpyrexia. Late
infantile- and juvenile- onset forms with longer survival
periods are also seen, and adults may present with weak-
ness, loss of manual dexterity, and paresthesia in their
extremities [1]. The prevalence of Krabbe disease is ap-
proximately one in 100,000 in the US and Europe [5]
with higher frequencies in the Druze and Muslim Arabs
in Israel [6].
Mutations in the GALC gene (14q31) cause Krabbe
disease [7], and numerous nonsense, missense, small in-
sertion, and small deletion mutations spanning the en-
tire length of the GALC gene have been described [3].
The most common mutation, consisting of approxi-
mately 40% of alleles from affected individuals with
European ancestry and 35% of alleles from those with
Mexican ancestry, is a 30-kb deletion beginning in in-
tron 10 and extending nine kb beyond the polyadenyla-
tion signal [3,8,9]. The 30-kb deletion mutation results
in the classic infantile form of the disease in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 GALC Mutations Identified in 33 Biochemically
Confirmed Krabbe Disease Patients at Emory Genetics
Laboratory




Two point mutations 16 16/33 = 48.5%
One point mutation and
one 30-kb deletion
8 8/33 = 24.2%
Two 30-kb deletions 4 4/33 = 12.1%
One known mutation and
one large deletion or duplication
3 3/33 = 9.1%
One known mutation and
negative array CGH
2 2/33 = 6.1%
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mosomes) with another mutation associated with severe
disease [3].
There are few reports of any other large deletions or
large duplications encompassing the GALC gene. The
techniques currently available for detecting single- and
multi-exon deletions and duplications include multiplex
PCR, quantitative PCR, Southern blotting, multiplex
ligation-dependent probe amplification (MLPA), detec-
tion of virtually all mutations-SSCP (DOVAM-S), and
single condition amplification/internal primer sequen-
cing (SCAIP). Due to the difficulty and complexity of
test development to routinely and reliably detect dosage
differences, clinical laboratories have not offered this
testing, and therefore data on the presence of these types
of mutations are lacking.
To further explore the deletion/duplication mutation
spectrum of the GALC gene, we have developed a com-
prehensive mutation detection strategy which begins
with sequence analysis of the GALC gene in combination
with mutation-specific testing for the 30-kb deletion. If
two mutations are not found using this approach, des-
pite an established biochemical diagnosis for the patient,
this testing is followed by targeted array comparative
genomic hybridization (CGH) to look for copy number
changes within the GALC gene. Here we present muta-
tion identification statistics for GALC analysis at Emory
Genetics Laboratory (EGL); we also identify two novel
GALC deletions and describe the only large GALC dupli-
cation reported in an individual with Krabbe disease.
Results
Emory Genetics Laboratory (EGL) started offering array
CGH-based deletion/duplication testing for the GALC
gene in January of 2008. From January of 2008 through
August of 2011, approximately 100 samples were sub-
mitted to EGL for full GALC gene analysis. There were
33 cases in which we performed complete GALC gene
analysis (sequence analysis with 30-kb deletion analysis
followed by array CGH deletion/duplication analysis, if
necessary). These cases included samples from indivi-
duals reported to be enzymatically or clinically affected
by Krabbe disease, and also paired parental samples
from cases in which the affected individual was
deceased. The remainder of the samples were not in-
formative for our study and included samples for which
no clinical information was submitted, samples sent for
carrier testing in individuals with a family history of
Krabbe disease in which the familial mutation was not
known, and samples sent for comprehensive carrier test-
ing from individuals with partners known to be carriers
for Krabbe disease. Analysis began with sequencing of
the 17 exons and flanking intronic regions of the GALC
gene, along with allele-specific PCR analysis for thecommon 30-kb deletion. If a mutation(s) was not found,
the ordering physician had the option of reflex testing
with array CGH to detect single and multiple exon dele-
tions and duplications.
Results of GALC analysis for the 33 cases of confirmed
Krabbe disease are given in table 1. In 28 of the 33 cases
(84.8%), both mutations were identified via sequence
analysis in combination with analysis for the 30-kb dele-
tion. Sixteen of these cases had two mutations identified
through sequence analysis, eight had one mutation iden-
tified through sequence analysis and one copy of the 30-
kb deletion, and four had a homozygous 30-kb deletion.
In an additional three of the 33 cases (9.1%), sequence
analysis with analysis of the 30-kb deletion identified
one mutation, while reflex deletion/duplication testing
identified a second mutation; these cases are discussed
in more detail below as cases 1-3. The overall detection
rate for two mutations using a combination of sequence
analysis and array-CGH deletion/duplication testing was
therefore 31/33 (93.9%).
In two of the 33 cases (6.1%), comprehensive GALC
mutation analysis, including sequence analysis, 30-kb de-
letion analysis, and deletion/duplication analysis, failed
to identify two known mutations. When only one muta-
tion is identified in individuals with a biochemical diag-
nosis of a recessive disease, it is EGL’s customary
practice to design a second set of PCR primers for the
entire gene involved. Resequencing of the GALC gene
with an alternative primer set also failed to identify a
second mutation in these individuals, reducing the prob-
ability of allele drop out. In one of the two cases, the
proband was deceased but reportedly had clinical fea-
tures consistent with Krabbe disease and an enzymatic
diagnosis of Krabbe disease from another laboratory (la-
boratory reports of the enzyme analysis were not pro-
vided to EGL). Sequence analysis with 30-kb deletion
analysis of the parents identified one copy of the 30-kb
deletion in the mother, but was negative in the father.
Reflex deletion/duplication testing in the father was also
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chemical diagnosis of Krabbe disease from another la-
boratory; no other information on the proband was
provided. Sequence analysis with 30-kb deletion analysis
identified one missense mutation and one intronic vari-
ant of unknown clinical significance (c.909-10A>G;
IVS8-10A>G) in the affected individual. Reflex dele-
tion/duplication testing was negative. Testing the par-
ents of the second individual was recommended to aid
in interpretation of the unknown variant, but has not
been ordered at EGL to date.
Case 1
Case 1 was an eight-month-old Caucasian male reported
to have deficient GALC enzyme activity. Sequence ana-
lysis with 30-kb deletion analysis identified one copy of a
five-bp deletion in exon 16 of the GALC gene. A second
mutation was not identified. After the affected individual
passed away, samples from the parents were sent to EGL
for testing. The individual’s mother was found to carry
the five-bp deletion. Array-CGH deletion/duplication
testing of the individual’s father detected a 6.9-kb dele-
tion of exon 8 (see figure 1).
Case 2
Case 2 was a one-year-old Caucasian female reported to
have deficient GALC enzyme activity by blood assay and
by fibroblast assay, and clinical features consistent with
Krabbe disease. Sequence analysis with 30-kb deletion
analysis identified one copy of the 30-kb deletion in this
individual. A second mutation was not identified. Test-
ing of the parents indicated that the child’s mother was
the carrier of the 30-kb deletion. Array-CGH deletion/
duplication analysis of the individual’s father revealed a
novel 11-kb duplication encompassing exons 11 through
14. Subsequent deletion/duplication testing of the
affected individual revealed a complex copy number pat-
tern in the GALC gene resulting from the overlapping
combination of the 30-kb deletion, which extends from
exons 11 through the end of the gene, and a duplication
of exons 11 through 14 (see figure 2). In this individual,
the combination of a deletion and a duplication resulted
in an array result with normal copy number for exons
11 through 14, while exons 15 through the end of the
gene were deleted. In the absence of parental testing,
this combined set of copy number changes would have
been difficult to detect and interpret. This individual
was confirmed to be the same individual reported in
[10] and is the only report of a large duplication in the
GALC gene to date.
Case 3
Case 3 was a 17-month-old East Indian female. Testing
in another laboratory indicated deficient GALC activityand a homozygous single base pair deletion in exon 1 of
the GALC gene. Testing of this individual’s parents indi-
cated that the mother was a carrier of the single base
pair deletion, but testing for the mutation in the father
was negative. Samples were submitted to EGL for array-
CGH deletion/duplication testing for the affected indi-
vidual and her father. This testing revealed a deletion of
exons 1 through 6 in both individuals (see figure 3). The
deletion that the affected individual inherited from her
father caused the mutation inherited from her mother to
appear homozygous by sequence analysis.
Discussion
Array CGH is currently being used successfully in many
molecular cytogenetic laboratories to detect gross altera-
tions in the human genome. Most cytogenetic arrays,
however, are not designed to detect small (intragenic)
deletions and duplications. The development of a clinical
test for detecting intragenic copy number changes has
the potential to raise the mutation detection rate for
tested diseases, thereby improving molecular diagnosis
of affected individuals. Gene-targeted array CGH offers
a powerful alternative to the current methods used for
detecting these mutations.
We have adapted array CGH technology and success-
fully shown that it can detect intragenic deletions and
duplications in a large set of genes, including GALC,
using a single array [11]. A study by Aradhya et al.
demonstrated that gene-targeted array CGH was able to
identify partial or whole gene deletions and duplications
in approximately 5% of a clinical cohort sent to a diag-
nostic laboratory for testing [12]. When broken down by
mode of inheritance, the positive rate approximately 5%
for autosomal dominant genes, approximately 10% for
autosomal recessive genes, and approximately 3.5% for
X-linked genes. They conclude that intragenic copy
number mutations are more prevalent that previously
suspected in Mendelian disorders and should be part of
their routine diagnostic workup. In addition, a study by
Wang et al. reported a 3% positive rate when using gene
targeted array CGH to identify deletions and duplication
in a mitochondrial and metabolic patient cohort, and
conclude that gene targeted array CGH is useful as a
complementary diagnostic test for gene sequence ana-
lysis [13].
The case reports presented here demonstrate the util-
ity of gene-targeted array CGH in clinical molecular
diagnostics to improve and clarify mutation detection, as
well as to identify copy number mutations that other-
wise would have been missed by conventional analysis.
As case 3 illustrates, apparently homozygous mutations
in affected individuals should be verified by testing
parents for the mutation and/or performing deletion/
duplication analysis on the affected individual to rule
Figure 1 Case 1. A. Pedigree of the proband and parents. A filled symbol indicates the affected individual; symbols with a dot in the middle
indicate carriers. GALC genotypes are given for each individual under the respective symbol. Sequence analysis with 30-kb deletion analysis
identified one copy of a five-bp deletion in exon 16 in the proband and his mother. A second mutation was not identified. Array CGH analysis
was performed on the proband’s father to identify the second mutation. B. GALC array CGH results for the father. A diagram of the GALC gene is
given above the results with exon numbers indicated. The father carries a deletion of exon 8 of the GALC gene. (The presence of the deletion of
exon 8 in the proband is inferred, as the proband passed away before deletion/duplication analysis was performed).
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and a deletion on the other allele. Of the 11 individuals in
this study with apparently homozygous mutations identi-
fied by sequence analysis with 30-kb deletion analysis
(seven point mutations and four 30-kb deletions), parental
samples were submitted on only three; in all three cases,
the parents were shown to each carry one copy of the now
verified homozygous mutation identified in the child.
Without parental testing on the other eight cases, it is not
possible to rule out the presence of a deletion, possibly
leading to an underrepresentation of the frequency of
novel deletions in the GALC gene.
In addition, the novel 11-kb duplication of exons 11-
14 in case 2 would not have been detected by the use of
traditional methodologies. This duplication normalizesthe copy number in the proband from exons 11-14, in
spite of the fact that the proband carries the common
30-kb deletion on the other allele. The detection of a de-
letion and duplication in trans in the same gene with
partially overlapping exons clearly proved the power of
aCGH to detect gene-targeted deletions and duplica-
tions. The better able we are to detect mutations, the
more options there will be for molecular prenatal testing
and carrier testing in family members.
Conclusions
An algorithm for molecular testing for Krabbe disease is
given in figure 4. First, genetic counselling and molecu-
lar testing for Krabbe disease can be offered to indivi-
duals with clinical symptoms, low levels of GALC
Figure 2 Case 2. A. Pedigree of the proband and parents. A filled symbol indicates the affected individual; symbols with a dot in the middle
indicate carriers. GALC genotypes are given for each individual under the respective symbol. Sequence analysis with 30-kb deletion analysis
identified one copy of the 30-kb deletion in the proband and her mother. A second mutation was not identified. Array CGH analysis was
performed on the proband’s father to identify the second mutation, which was confirmed in the proband. B. GALC array CGH results for the
father (top), mother (middle), and proband (bottom). A diagram of the GALC gene is given above the results with exon numbers indicated. The
father carries a duplication of exons 11 through 14, while the mother carries the 30-kb deletion of exons 11 through 17. The combination of the
duplication and deletion in the proband yields a neutral copy number for exons 11 through 14 (boxed region), since she has two copies of those
exons (both from her father and none from her mother), while exons 15 through 17 are deleted (present in only one copy from her father).
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should begin with GALC gene sequence analysis, along
with allele-specific PCR for the 30-kb deletion, as these
methods have the highest detection rate and are cost
effective. If these methods do not identify two known
mutations, GALC array CGH deletion/duplication analysis
should be offered. If two mutations are identified, prenatal
testing can be offered after parental testing to confirm
that the two mutations are in trans. Since sequence ana-
lysis alone cannot distinguish a homozygous mutation
from a sequence mutation that lies in trans with a dele-
tion in the same gene, mutation-specific testing of both
parents of individuals with an apparently homozygous
mutation is especially important. Parental testing shouldbe followed by deletion/duplication testing in those
cases in which one parent tests negative for the muta-
tion. Once two mutations have been identified and
confirmed in parental samples, testing by known mu-
tation analysis would also be possible for other
affected family members or as carrier testing in adult
family members.
This study of 33 Krabbe cases reveals that array CGH
deletion/duplication analysis of the GALC gene increased
the rate of detection of two mutations from 84.8%, for
sequence analysis with 30-kb deletion analysis, up to
93.9%, and enabled us to uncover three previously un-
reported copy number mutations. In addition to the
33 cases presented here, there were also three other
Figure 3 Case 3. A. Pedigree of the proband and parents. A filled symbol indicates the affected individual; symbols with a dot in the middle
indicate carriers. GALC genotypes are given for each individual under the respective symbol. Sequence analysis performed in another laboratory
identified an apparently homozygous one nucleotide deletion mutation in the proband. One copy of the mutation was identified in the
proband’s mother, but her father was negative. Array CGH analysis was performed on the proband’s father to identify a suspected deletion,
which was confirmed in the proband. B. GALC array CGH results for the father (top) and proband (bottom). A diagram of the GALC gene is given
above the results with exon numbers indicated. Both the father and the proband have one copy of a deletion of exons 1 through 6. The deletion
inherited from her father made the mutation in exon 1 inherited from her mother appear homozygous in the proband by sequence analysis.
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analysis failed to identify two known mutations, but for
which reflex deletion/duplication testing was not
ordered. In one case, only one mutation was detected
though sequence analysis, whereas in the other two
cases, one known mutation and one variant of unknown
clinical significance were detected through sequence
analysis. In all three cases, deletion/duplication analysis
and parental testing were recommended in the hope
that a second mutation could be identified or the signifi-
cance of the variants might be clarified; none of this test-
ing, however, has been ordered at EGL to date. Ultimately,
further GALC array CGH deletion/duplication testing inclinical laboratories will likely refine these statistics and
identify other novel mutations.
Methods
Sequencing
Oligonucleotide primers were designed to amplify the 17
coding exons of the GALC gene in 16 fragments. (Oligo-
nucleotide sequences are available from the authors
upon request.) PCR products were analyzed on a 2%
agarose gel, after which the remainder of the PCR prod-
uct was purified using a Millipore Ultrafiltration PCR
purification kit (Millipore, Billerica, MA). Sequencing
reactions were prepared in a 10-ul reaction volume using
Figure 4 Algorithm for testing for Krabbe disease in affected individuals.
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City, CA). Each PCR product was sequenced in both
directions according to ABI recommendations using uni-
versal M13 sequencing primers. Sequenced PCR pro-
ducts were purified using SephadexW cleanup plates by
Edge Biosystems (Gaithersburg, MD) according to the
manufacturer’s recommendation. Samples were heat-
denatured for 5 minutes and loaded onto an ABI 3730xl
sequencer. Sequence data were analyzed using Mutation
SurveyorW v3.1 (Softgenetics, PA) and SeqScapeW (Ap-
plied Biosystems, Foster City, CA).
Allele-specific PCR
The allele-specific PCR assay for the 30-kb GALC dele-
tion was designed by Rafi et al., 1995. Three primers,
one sense and two antisense, were used to amplify the
wild-type and mutant alleles. The PCR products were
analyzed on a 2% agarose gel. A wild-type allele yields a
615 bp PCR product whereas a mutant allele yields a
320 bp PCR product.
Array CGH
Array design
The targeted gene high-resolution oligonucleotide CGH
array was custom designed on Oxford Gene Technolo-
gies (OGT) 180 K platform to detect deletions and
duplications in 175 genes associated with various geneticdisorders. Long oligonucleotides (~45–60 mer) were
used to design the array, with repeat sequence masking
implemented to ensure greater sensitivity and specificity.
The GALC gene was covered by 431 probes with 116
probes covering the 17 exons at an average spacing of
15 bp between probes. The intronic region was covered
by 315 probes at an average spacing of 25 bp between
probes. Use of intronic oligonucleotide probes allows us
to detect dosage changes within the entire genomic re-
gion of the gene and determine the approximate
breakpoints.
Experimental set up
DNA extraction was performed on patient DNA using a
Gentra Puregene DNA extraction kit according to the
manufacturer’s instructions. Male and female wild-type
control DNA was obtained from Promega, Inc. Each pa-
tient and reference DNA sample was sonicated, such
that the DNA fragment size was between 200-5,000
bases and verified on a 1% agarose gel. Patient and refer-
ence DNA samples were labeled using Klenow enzyme
(NEB) and Cy3 or Cy5 9mer wobble primers (TriLink
Technologies), respectively. After labeling, each sample
was purified by isopropanol precipitation and reconsti-
tuted in ultra-pure water. We combined 4 ug each of la-
beled patient and reference DNA, and the products were
desiccated in a vacufuge (Savant DNA 120), then
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with Cy3 and Cy5 control CPK6 50mer oligonucleotides.
This mixture was hybridized to a NimbleGen targeted
gene CGH array for 16-20 hours at 42 °C in a Maui
Hybridization system (BioMicro Systems). The array has
389,587 unique sequence probes with an average spacing
of 10-bp within coding regions and 25-bp within in-
tronic regions, allowing for detection of copy number
changes and breakpoints as small as 100-bp within the
entire coding region. Arrays were then washed according
to the manufacturer’s recommendation and immediately
scanned on a GenePix 4000 scanner (Molecular Devices).
After scanning, data were extracted from images, and
within-array normalization was accomplished using
manufacturer-provided software (NimbleScan). Normal-
ized log(2) ratio data were analyzed using two different
analysis programs: SegMNT and DNA copy NimbleScan
(NimbleGen Systems, Inc.). Both software programs re-
port breakpoints for predicted deletions or duplications
in the patient or test sample relative to the reference
and also display results in a bar graph where the y-axis
indicates gain or loss of material (1 = gain, 0 = normal,
-1 = loss), while the x-axis indicates the position of each
feature on the chromosome.
Data files (.gff ) generated from different averaging
windows using NimbleScan software were parsed using
a custom program (Nimkit) that was developed in-
house. Nimkit enables the laboratory to select and
analyze only the gene of interest. Nimkit generates a
gene-specific report summarizing breakpoints detected
in the gene of interest, the respective log(2) ratios, and
the exons present at each region. All other regions are
masked and not analyzed by Nimkit, preventing genetic
analysis of genes for which clinical testing was not
requested, in compliance with HIPAA requirements.
Array quality was assessed by control resequencing oli-
gonucleotides on each array that correspond to synthetic
sequences designed to have no cross-hybridization po-
tential to any known sequence. This sequence was
designed to have three distinct sequencing domains with
different characteristics: A, B, and C domains. Resequen-
cing was performed on both the forward and reverse
strands, so that the resequencing report has six different
scores for the Cy3 channel and six distinct scores for the
Cy5 channel: A-forward and A-reverse, B-forward and
B-reverse, C-forward and C-reverse.
The “A” domain contained long runs of G nucleotides
that can be difficult to synthesize. The “B” domain con-
tained a large perfect hairpin sequence. The “C” domain
contained a straightforward domain that should always
resequence. Failure of domain “C” indicated a cata-
strophic failure. Control DNA was spiked into each ex-
periment for both CGH and resequencing arrays. A
score from 0-100% was obtained that indicated thesequence fidelity and correlated well with the overall
performance of a microarray experiment [14].
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